6.
PARG in vitro cleavage assay (Fig. S9 and S11) . Error in legend: t=0 should be without PARG and not without PARP1. Why does short-chain PAR disappear after 15 min timepoint? Are small PAR fragments no longer detected by the antibody? Would be nice to have a positive (canonical PARG with endo-and exo activity) and a negative (TcPARG) in this assay for comparison. This data seems critical for the conclusions of the manuscript and should be presented in the main text.
7.
No data to support the statement 'The detected short-chain PAR did not likely result from removal of short PAR from PARP1 but rather from endo-cleavage of O-glycosidic linkages of longchain PAR because PARG could not hydrolyze the ester bond attached to protein'.
8.
ITC data: what binding model was used for fitting the data? What is the evidence suggesting that mutation of Thr267 'impairs the ability of binding to the internal ADP-ribose units (Table 2)? 9.
Based on the findings presented in this paper, are most prokaryotic PARG predicted to be exo-glycohydrolases or endo-and exo-glycohydrolases? This question should be addressed by comparing PARG sequences. Such a discussion would also benefit from comparisons with eukaryotic canonical PARG enzymes.
Additional minor points:
1.
More details should be provided to describe the dot blot assay: how much material was deposited or culture volume used? Which secondary antibody? Which mode of detection (radiolabel, colorimetric etc.)?
2.
Page 11: Co-IP with PAR antibody confirmed co-localization. Do the authors mean 'interaction'? The following statement is also unclear: '..thus suggesting that the PAR signal was occasioned from NAD+'. Do you mean, PAR signal is dependent on the availability of NAD+?
3.
Last line of page 16, '…suggested that the exo-glycohydrolase activity was blocked'. This should be the 'endo-glycohydrolase activity'. Also on page 20, line 375: 'Our data suggest the presence of exo-glycosidic cleavage of PAR in prokaryotic microorganisms.' It should be both endoand exo-activities.
4.
Description of structural data regarding mutant DrPARG in Fig. 6 is unclear.
5.
In the results section, it is not clearly stated that MD simulations were performed with a tri-ADP-ribose, but only that a model was created. This is not the same and should be clarified.
Cho and colleagues solved the crystal structure of ADP-ribose-bound bacterial type PARG from Deinococcus radiodurans (DR). The authors further suggested that the DR PARG possesses both exoand endoglycohydrolase activites (in contrast to the previously characterised bacterial PARG from Thermomonospora curvata). Finally, the authors constructed the PARG-deficient Deinococcus strain and provided the first in vivo evidence of endogenous poly(ADP-ribose) (PAR) metabolism in any bacterial organism. This paper is timely and well-written; most of the conclusions in the paper are supported by the results.
Major comments: Figure 3 . Please provide one panel where the PAR in the cell lysate is analysed by the WB rather than dot blot. This would also give an idea of the size of the PARylated proteins. It would be important to try both the PAR antibody as well as the anti-pan-ADP-ribose binding reagent (Millipore). Figure 3D . It would be ideal to see here an alternative/more direct evidence that Deinoccocus cell is permeable for biotinylated NAD. Although the overall work is clearly presented and the structural studies are sound, this study would benefit from additional experiments and analyses, and care should be taken to avoid overstatements. The major points are listed below.
An in-depth structural comparison of the DrPARG structure with the eukaryotic homologues should be performed as well as a comparative study with TcPARG, since canonical PARGs possess both exo-and endo-activity and would thus be more similar to DrPARG. How different are their active sites?
We are very grateful to the reviewer for this point. A detailed comparison of the ADP-ribose binding pocket in DrPARG, TcPARG, and HsPARG was performed as suggested and re-drawed Fig. 2 and Supplementary Fig. S6 for the comparison. The results showed that both canonical and bacterial PARGs adopted similar organization of amino acids interacting with ADP-ribose in the active sites, as well as their catalytic mechanism. However, structural features such as the ribose cap (only appears in bacterial PARG) block the extension of n+1 ADP-ribose moiety and distinguish bacterial PARG from canonical PARG. DrPARG also has the ribose cap, however, it can act as endo-PARG because Thr267 does not confer steric hinderance.
Related to point 1, a sequence alignment of PARGs should be provided including
the sequences discussed in the manuscript (TcPARG, DrPARG, human PARG etc.) .
How conserved are Thr267 and Glu112? Do most bacterial species have an Arg like TcPARG or a Thr like DrPARG?
Thanks for the comments. A structure-based sequence alignment was performed and shown in Supplementary Fig. S6 . Glu112 is the conserved catalytic residue among bacterial and canonical PARG. Thr267 is not conserved among bacterial and canonical PARG because it resides in the ribose cap structure which only found in bacterial PARG. When we performed BLAST against DrPARG sequences, potential bacterial PARGs can be found. We aligned the sequences of the proteins and found the occurrence of Thr is higher than Arg in the position corresponding to Thr267.
Many of the proteins have Thr or Val in the position corresponding to Thr267. Fig. 3A We are very grateful to the reviewer for this point. The assay was re-done by quantifying the total protein in the lysates. 3mL culture were taken for preparing the lysate and total protein was quantified using Bradford assay before dot blotting (Fig.   3E ). We are very grateful to the reviewer for this point. As reviewer's suggestion, Pulsed
The quality of dot blots is insufficient. Ponseau staining reveals different amounts were deposited (see also minor point 1 below) and the data presented in

Examples of overstatements: 'PARG might be involved in
Field Gel Electrophoresis (PFGE) experiment was performed examining the role of DrPARG in DNA damage repair and the results showed disruption of DrPARG compromises recovery of genome after radiation damage ( Supplementary Fig. S9 ), suggesting DrPARG is involved in DNA damage repair. In addition, another experiment RAPD (Random-Amplified Polymorphic DNA) for evaluation of DNA-damage repair was performed and the results also indicated DrPARG is involved in DNA repair ( Supplementary Fig. S10 ).
PARG in vitro cleavage assay (Fig. S9 and S11). Error in legend: t=0 should be without PARG and not without PARP1. Why does short-chain PAR disappear after 15 min timepoint? Are small PAR fragments no longer detected by the antibody? Would be nice to have a positive (canonical PARG with endo-and exo activity) and a negative (TcPARG) in this assay for comparison. This data seems critical for the conclusions of the manuscript and should be presented in the main text.
Thanks for the reviewer's kind reminding. We corrected the figure legend and added positive (HsPARG) and negative (TcPARG) controls as suggested.
The PAR monoclonal antibody 10H preferentially recognize PAR >20 mer. After 15 min reaction, short-chain PAR may be processed to smaller fragments beyond the detection limit of antibody and we added the description in the result section of main text. We also added the controls of TcPARG and HsPARG to the assay (Fig. 5B) .
No data to support the statement 'The detected short-chain PAR did not likely result from removal of short PAR from PARP1 but rather from endo-cleavage of O-glycosidic linkages of long-chain PAR because PARG could not hydrolyze the ester bond attached to protein'.
We are very grateful to the reviewer for this point. Thus, we conducted de-MARylation experiments on DrPARG as shown in Fig. S15 . The results suggested DrPARG is incapable of removing glutamate-or serine-linked mono ADP-ribosylation. We also modified the sentence in the main text.
ITC data: what binding model was used for fitting the data? What is the evidence suggesting that mutation of Thr267 'impairs the ability of binding to the internal ADP-ribose units (Table 2)?
The ITC data were fitted using an independent binding model. The mutation of Thr267 may impair the binding of internal ADP-ribose unit was inferred from the increased Km of T267 mutant in Table 2 not the ITC data. We deleted the sentence to avoid misunderstanding.
Based on the findings presented in this paper, are most prokaryotic PARG predicted to be exo-glycohydrolases or endo-and exo-glycohydrolases? This question should be addressed by comparing PARG sequences. Such a discussion would also benefit from comparisons with eukaryotic canonical PARG enzymes.
We are very grateful to the reviewer for this point. We performed BLAST against the sequence of DrPARG and many microbial proteins bearing the PARG signature motif were identified, suggesting they may be potential PARGs. We aligned the sequences of those proteins and found many of them have threonine and valine in the position corresponding to Thr267, suggesting they may be endo-PARGs. However, the number of bacterial endo-PARG may be underestimated since Thr267 is not the only determinant of endo-glycohydrolase activity. The endo-activity may be better inferred when structural flexibility is taken considered. Thanks for the reviewer's kind reminding.
Co-IP experiment was used for examining the incorporation of labelled-NAD + into PAR and verifying the existence of endogenous PAR since NAD + is the substrate for generating PAR. We think environmental abundance of NAD + may affect endogenous PAR level because when we supplemented NAD + to bacterial culture, PAR signal increased (Fig. 5D) . We corrected the statement to "…suggesting that the PAR signal was dependent on the availability of NAD + ".
Last line of page 16, '…suggested that the exo-glycohydrolase activity was blocked'. This should be the 'endo-glycohydrolase activity'. Also on page 20, line 375: 'Our data suggest the presence of exo-glycosidic cleavage of PAR in prokaryotic microorganisms.' It should be both endo-and exo-activities.
Thanks for the reviewer's kind reminding. We modified the sentences to "…which suggested that the endo-glycohydrolase activity was impaired" and "suggest the presence of both exo-and endo-activities of PARG in prokaryotic microorganisms."
as suggested. Fig. 6 is unclear.
Description of structural data regarding mutant DrPARG in
We added additional descriptions regarding the space groups of T267R and T267K structures and their RMSD to WT structure, as well as the differences in solvent accessible surface of ADP-ribose binding site in WT, T267R, and T2677K structures (Fig. S17) .
In the results section, it is not clearly stated that MD simulations were performed
with a tri-ADP-ribose, but only that a model was created. This is not the same and should be clarified.
Thank you for your kind reminding. MD simulation was for minimization and refinement of the complex model. We modified the sentence to "we constructed the structural model of DrPARG in complex with tri-ADP-ribose using MD simulation"
Reviewer #2 (Remarks to the Author):
Cho and colleagues solved the crystal structure of ADP-ribose-bound bacterial type PARG from Deinococcus radiodurans (DR). The authors further suggested that the DR PARG possesses both exo-and endoglycohydrolase activites (in contrast to the previously characterised bacterial PARG from Thermomonospora curvata). Finally, the authors constructed the PARG-deficient Deinococcus strain and provided the first in vivo evidence of endogenous poly(ADP-ribose) (PAR) metabolism in any bacterial organism. This paper is timely and well-written; most of the conclusions in the paper are supported by the results.
Major comments: We are very grateful to the reviewer for this point. As suggestion from reviewer, we provided a panel for the PAR in the cell lysate analyzed by the WB using both PAR antibody and the anti-pan-ADP-ribose binding reagent (Millipore) shown in Fig. 3C .
Methods and related statement were descripted in main text. Figure 3D . It would be ideal to see here an alternative/more direct evidence that Deinoccocus cell is permeable for biotinylated NAD.
Thanks for reviewer's comments. To provide the evidence, we added a control treating the culture with biotin (Fig. 3E) . In the preIP sample analyzed by dot blot using biotin antibody. Thanks for reviewer's suggestion. We provided a dot blot for treating the cell lysates of ΔPARG cell with recombinant HsPARG (Fig. 3H) . We are very grateful to the reviewer for this point. As suggestion from reviewer, we 
Does the growth of Deinococcus in the presence of 3-aminobenzamide block cellular PAR signal (as demonstrated for PAR formation in Streptomyces species)?
We are very grateful to the reviewer for this point. Thus, we treated the R1 cells with various amounts of 3-aminobenzamide for overnight culture. The result of dot blot
